Merit Medical Systems Stock Climbs 25% On A 13-Day Winning Streak
A long winning streak for Merit Medical Systems has investors looking closer at the fundamentals supporting the run.
Shares of Merit Medical Systems (MMSI) have gained 25% in a run that has added about $1.1 billion to the company’s market value.
The stock has now moved higher for 13 consecutive trading days, bringing its total valuation to about $5.4 billion. For anyone holding the stock, this represents a significant short-term return.
MMSI Versus The S&P 500, Streak And Beyond
- 28 S&P 500 Stocks Hit 52-Week Highs On Tuesday
- The 52-Week-High List: 53 Small Cap Names On Tuesday
- 1 S&P 500 Stock Just Touched 52-Week Lows
- The 52-Week-High List: 17 Large Cap Names On Tuesday
- Stocks At 52-Week Lows: Tuesday’s Full List
- S&P 500 Movers | Winners: KKR, AXON, APO | Losers: APP, VTR, DDOG
Here is how MMSI stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | MMSI | S&P 500 |
|---|---|---|
| 1D | 1.5% | -0.3% |
| 13D (Current Streak) | 24.6% | 4.3% |
| 1M (21D) | 24.4% | 2.8% |
| 3M (63D) | 51.1% | 4.3% |
| YTD 2026 | 3.4% | 12.9% |
| 2025 | -8.9% | 16.4% |
| 2024 | 27.3% | 23.3% |
| 2023 | 7.6% | 24.2% |
Is there fundamental support for this run?
The move appears to be specific to the stock rather than a simple market lift. Over the same 13 trading days the S&P 500 returned +4.3%. The market may be weighing a growth story that outpaces the median S&P 500 company, with revenue over the last twelve months growing 10.2% versus a median of 8.3%.
That growth comes with a higher valuation, as MMSI trades at a price-to-earnings multiple of 37.4, above the S&P 500 median of 23.8. For context on market momentum, 68 S&P 500 stocks are currently on winning streaks of 3 days or more.
So how should an investor think about a streak?
A streak this long is primarily a signal of sustained investor attention. It is not, by itself, a reason to act. The disciplined approach is to treat the new price as a prompt to re-evaluate the underlying business.
The data on growth, margins, and valuation provides a starting point for assessing whether the current price of about $91.11 a share reflects the company’s financial footing.
If you are hunting for strength that has more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
Those drawn to the strength but not the single-name risk have another route: our ETF Scorecard shows how the healthcare funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Momentum Is A Tailwind, Not A Plan
Riding a stock that rises every day feels effortless, and that is precisely the danger: the same momentum that built this run can reverse without notice, and one name’s reversal should never be able to reset your whole year.
That is what the Trefis High Quality (HQ) Portfolio is for: about 30 quality businesses screened for the fundamentals that survive momentum’s mood swings, held with rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Watch the runs; own the resilience.